ALPHA 1 BIOMEDICALS APPOINTS HAUTALA TO VICE PRESIDENT, CORPORATE DEVELOPMENT
ALPHA 1 BIOMEDICALS APPOINTS HAUTALA TO VICE PRESIDENT,
WASHINGTON, Jan. 22 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM), today announced it has appointed Judith A. Hautala, Ph.D. to the position of vice president, corporate development.
Previously, Hautala was vice president, technology development, at Genex Corporation (now a part of Enzon, Inc.) with responsibility for research and development activities and intellectual property matters. She held earlier positions at Genex in both business development and research. Hautala received her Ph.D. degree from Northwestern University and performed postdoctoral research at Memorial Sloan- Kettering Cancer Research Institute in New York.
Vincent F. Simmon, Ph.D., president and chief executive officer of Alpha 1, said: "Dr. Hautala's extensive scientific, business and patent experience will be of great value as the company moves forward toward obtaining regulatory approval for Thymosin alpha 1 for treating various diseases. Dr. Hautala will become a primary spokesperson for the company to the press and investment community."
Alpha 1 Biomedicals, Inc., is a Washington-based company engaged in the development of pharmaceutical products. The company's lead product, Thymosin alpha 1, is currently being evaluated in a multi-center Phase III clinical trial in the United States for the treatment of chronic hepatitis B, and is in a single-center Phase III clinical trial in combination with alpha interferon for the treatment of chronic hepatitis C.
/CONTACT: Judith A. Hautala of Alpha 1, 202-628-9898; or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1/
(ALBM) CO: Alpha 1 Biomedicals, Inc. ST: District of Columbia IN: MTC SU: PER
GK -- NY014 -- 2096 01/22/92 09:08 EST